Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Eur Heart J. 2021 Apr 7;42(14):1368-1378. doi: 10.1093/eurheartj/ehaa601.
No abstract available

Keywords: Acute cardiac care; Acute coronary syndrome; Angioplasty; Anticoagulation; Antiplatelet; Apixaban; Aspirin; Atherothrombosis; Betablockers; Bivalirudin; Bleedings; Bypass surgery; Cangrelor; Chest pain unit; Clinical cases; Clopidogrel; Dabigatran; Diabetes; Dual antithrombotic therapy; Early invasive strategy; Edoxaban; Enoxaparin; European Society of Cardiology; Fondaparinux; Glycoprotein IIb/IIIa inhibitors; Guidelines; Heparin; High-sensitivity troponin; MINOCA; Myocardial infarction; Myocardial ischaemia; Nitrates; Non-ST-elevation myocardial infarction; Platelet inhibition; Prasugrel; Recommendations; Revascularisation; Rhythm monitoring; Rivaroxaban; Stent; Ticagrelor; Triple therapy; Unstable angina.

MeSH terms

  • Acute Coronary Syndrome* / drug therapy
  • Anticoagulants / therapeutic use
  • Drug Therapy, Combination
  • Fibrinolytic Agents / therapeutic use
  • Heparin / therapeutic use
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Heparin